{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000062","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.591395+00:00","generated_at":"2026-05-18T05:58:23.509098+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Keros doses first patient in Phase 3 RENEW trial of elritercept; $10M milestone from Takeda","bullets":["First patient dosed in Phase 3 RENEW trial of elritercept for adults with transfusion-dependent anemia with very low, low, or intermediate risk MDS.","Milestone payment of $10 million triggered from Takeda under global license agreement.","Keros received $200M upfront in Feb 2025; eligible for milestones exceeding $1.1B and tiered royalties.","RENEW is global, randomized, double-blind, placebo-controlled; primary endpoint is reduction in red blood cell transfusions."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000062","json":"https://secwatch.observer/filing/0001664710-25-000062.json","markdown":"https://secwatch.observer/filing/0001664710-25-000062.md","text":"https://secwatch.observer/filing/0001664710-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/0001664710-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/kros-20250717.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:58:23.509098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}